Ocular Therapeutix Inc (OCUL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) has a cash flow conversion efficiency ratio of -0.083x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-54.25 Million) by net assets ($654.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ocular Therapeutix Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OCUL total debt and obligations for a breakdown of total debt and financial obligations.
Ocular Therapeutix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocular Therapeutix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
H&R Real Estate Investment Trust
TO:HR-UN
|
0.007x |
|
AMP Limited
F:AMP
|
-0.012x |
|
Nava Bharat Ventures Limited
NSE:NAVA
|
0.158x |
|
BBMG Corp Class A
SHG:601992
|
-0.038x |
|
Alliance Financial Group Bhd
KLSE:2488
|
0.000x |
|
Jinfu Technology Co Ltd
SHE:003018
|
0.074x |
|
Goodyear Tire & Rubber Co
NASDAQ:GT
|
0.444x |
|
Triumph Group Inc
NYSE:TGI
|
-1.931x |
Annual Cash Flow Conversion Efficiency for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ocular Therapeutix Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see OCUL stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $654.31 Million | $-204.88 Million | -0.313x | +26.68% |
| 2024-12-31 | $315.34 Million | $-134.68 Million | -0.427x | +44.58% |
| 2023-12-31 | $91.13 Million | $-70.23 Million | -0.771x | +54.25% |
| 2022-12-31 | $35.38 Million | $-59.60 Million | -1.685x | -126.17% |
| 2021-12-31 | $88.00 Million | $-65.55 Million | -0.745x | -5.84% |
| 2020-12-31 | $76.09 Million | $-53.55 Million | -0.704x | -103.29% |
| 2019-12-31 | $-3.63 Million | $-77.58 Million | 21.371x | +1657.47% |
| 2018-12-31 | $35.88 Million | $-49.23 Million | -1.372x | +28.92% |
| 2017-12-31 | $26.15 Million | $-50.47 Million | -1.930x | -195.27% |
| 2016-12-31 | $52.01 Million | $-34.00 Million | -0.654x | -73.58% |
| 2015-12-31 | $89.59 Million | $-33.74 Million | -0.377x | -7.86% |
| 2014-12-31 | $58.70 Million | $-20.50 Million | -0.349x | -264.23% |
| 2013-12-31 | $-59.47 Million | $-12.64 Million | 0.213x | -21.25% |
| 2012-12-31 | $-46.61 Million | $-12.59 Million | 0.270x | -- |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more